

Olanzapine-associated hypothermia in an adolescent anorexic girl

Martine K. F. Docx^{1*}, Annik Simons², José Ramet³, Luc Mertens⁴, Paul Govaert¹

¹Department of Paediatrics, Queen Paola Children's Hospital, Antwerp, Belgium

²Department of Child Psychiatry, Queen Paola Children's Hospital, Belgium and University of Antwerp, Antwerp, Belgium

³Department of Paediatrics, University Hospital, Antwerp, Belgium

⁴Division of Cardiology, The Hospital for Sick Children, Toronto, Canada

Email: *martine.docx@zna.be, annik.simons@zna.be, jose.ramet@uza.be, luc.mertens@sickkids.ca, paul.govaert@zna.be

Received 28 June 2012; revised 27 July 2012; accepted 17 August 2012

ABSTRACT

This is a 12th case report on olanzapine induced hypothermia and based on the results of literature search, by far is the youngest case ever is reported. The hypothermia occurred during the refeeding phase, despite a weight gain since increasing the dosage from 5 mg to 7.5 mg olanzapine. Our recent literature search found 11 published cases of olanzapine treatment associated with hypothermia. Olanzapine acts on serotonin or dopamin receptors and has antagonistic properties on histaminergic, muscarinic and α -adrenergic receptors. Olanzapine mediates the hypothermic effect through antagonism at receptors other than dopamine.

Keywords: Anorexia Nervosa; Olanzapine; Hypothermia

1. BACKGROUND

The traditional definition of hypothermia is a drop in core temperature below 35°C. The hypothalamus, more precisely the hypothalamic pre-optic region, is assumed to work as a coordinating center with involvement of dopamine, serotonin, norepinephrin and α -adrenergic receptors [1-3]. Cerebrovascular autoregulation of our core temperature remains intact until below 25°C; the latter helps maintain the cortical blood flow [4]. The most common causes of hypothermia are due to environmental exposure to low ambient temperatures. Other causes are septicemia, diabetic ketoacidosis, malnutrition, multisystem trauma, acute spinal cord injury, prolonged cardiac arrest and hypothyroidism. Major side effects of olanzapine and other second-generation antipsychotics, like risperidone, quetiapine, aripipazole, paliperidone and ziprasidone are temperature dysregulation (mostly hyper-

thermia, less often hypothermia) and the neuroleptic malignant syndrome, a life threatening event. Other side effects seen by neuroleptic drugs are include sedation, weight gain, hyperglycemia, orthostatic hypotension, dizziness, constipation, urinary retention, discoloration of teeth and dental problems and occasionally seizures [3,5-9]. Drug may increase triglyceride, cholesterol and transaminase levels [10]. Olanzapine (Zyprexa[®]), an atypical antipsychotic drug, is considered for the management of psychosis, and is also used off-label for treating anorexic adolescents [11]. In a recent paper were olanzapine was used for the adjunctive treatment of adolescents with anorexia nervosa; the patients treated with olanzapine have a greater illness severity, acuity and comorbidity than the control population. Despite the inherent differences between both groups, the authors were unable to draw any firm conclusions regarding the potential efficacy of olanzapine and the rate of weight gain was not statistically different between both groups [10].

The mechanism of olanzapine-induced temperature dysregulation may include antagonism of the dopamine D2 and 5-hydroxytryptamine 2 (5HT2) receptors [9].

2. CASE REPORT

L. was a 14-year-old girl with a restrictive type of anorexia nervosa since the age of 13 years [BMI: 14.0 kg/m²] when she was admitted to our tertiary eating disorder unit. Her personal history was complicated at the age of 12 years by an ablation for Wolff-Parkinson-White syndrome. Her family history was noticeable for her paternal grandmother with bipolar disorder and her father with depression. She presented with hypothermia (34.5°C oral temperature electronic thermometer day 141 of her second admission) during refeeding, despite appreciable weight gain [BMI: 16.7 kg/m² day 0 at second admission to BMI: 18.1 kg/m² day 141]. On the first admission in the acute state 1 year ago and during the second admission several measurements of her body temperature had

*Corresponding author.

Table 1. Summary of cases published in PUBMED-Search: Hypothermia and olanzapine.

Author	Age (y)	Gender	Indication	Disease & Hypothermia	Dosage Olanzapine & Comedication	Treatment
1. Phan TG. <i>et al.</i>	37	F	Psychotic Disorder	Prader-Willi Syndrome Hypothermia	Single dose olanzapine & Risperdone	Cessation Olanzapine Start Levothyroxine
2. Hägg S. <i>et al.</i>	73	F	Schizophrenia	Somnolence Hypotension Prolonged QT-interval AV block type-1 Repeated episodes of hypothermia 31.5°C	4 hrs of the single dose olanzapine 10 mg & Perphenazine	Cessation Antipsychotic Treatment Warmed intravenous fluids Heating lamp Warmed blankets
3. Parris C. <i>et al.</i>	83	F	Bipolar Disorder	Dementia Catatonia Hypertension Hypothermia 33.1°C Lethargy	After 3 weeks 5 mg/d olanzapine & Lithium carbonate, Piroxicam, Clonazepam and Trazodone hydrochloride	Cessation all medication Warmed blankets Warmed intravenous fluids
4. Fukunishi I. <i>et al.</i>	54	M	Night Delirium	Visual hallucinations ESRD-hemodialysis Hypothermia 34.0°C	Olanzapine 2.5 mg/d for 10 days	Cessation olanzapine Pharmacokinetic Interactions in ESRD patient
5. Lee TW. <i>et al.</i>	84	M	Mixed Dementia (Alzheimer + Vascular)	Long-term hypertension Bradycardia (40 bpm) Hypotension (50/30 mm Hg) Hypothermia 35.6°C	Olanzapine 2.5 mg & Aspirin, Captopril, Zolpiclone	Cessation all medication Extra intravascular fluid
6. Blass DM. <i>et al.</i>	64	F	Bipolar Disorder	Type II Diabetes Mellitus Hypothyroidism Hypothermia 33.4°C	Gradually titrated olanzapine 2.5 to 6.25 mg & Gabapentin	Cessation Olanzapine Start Levothyroxine
7. Hung CF. <i>et al.</i>	17	M	Schizophreniform Disorder	Rhabdomyolysis CK (5525 U/L) Hypotension (90/50 mm Hg) Bradycardia (54 bpm) Hypothermia	After intramuscular injection once 5 mg olanzapine	Alkalized fluid infusion Forced diuresis Warmed blankets
8. Rasnayake LR. <i>et al.</i>	42	M	Paranoid Schizophrenia	Somnolence Reduced muscle tone Bradycardia (48 bpm) with J waves Hypotension (90/60 mmHg) Hypothermia 32.0°C	Since 6 years olanzapine 10 mg/d	Cessation Olanzapine Rewarming gradually Warm saline infusion
9. Kreuzer P. <i>et al.</i>	51	F	Catatonic Schizophrenia	BMI: 15 kg/m ² Hypothyroidism Hypothermia 30.0°C	16 days after increasing dose from 20 mg to 30 mg/d olanzapine & Lorazepam, Thyroxine	Cessation Olanzapine Cardiopulmonary Monitoring Warmed blankets Endocrine work-up
10. Kreuzer P. <i>et al.</i>	48	F	Catatonic Schizophrenia	Hypoxia (80%) Somnolent-Confused Light-rigid pupils Leukopenia (2900/ μ L) Hypothermia 31.0°C	Once olanzapine 5 mg	Cessation Olanzapine Rewarmed Cardiopulmonary monitoring
11. Kreuzer P. <i>et al.</i>	69	M	Acute Schizophrenic Disorder	Optic hallucinations Paranoia AV block type-3 Hypothermia 33.0°C	After single dose olanzapine 10 mg/d & Lorazepam 3 to 4.5 mg/d	Cessation Olanzapine Rewarmed

mia-unrelated to drug use has already been reported in anorexic patients with a BMI < 13 kg/m² and latent transient primary hypothyroidism or low T3 syndrome before refeeding [17]. In contrast, onset of hypothermia developed abruptly in our patient during the refeeding phase, when the BMI had already increased to 18.1 kg/m² and the thyroid function tests were normal. Also risperidone used in the first weeks for borderline-psychosis can also cause hypothermia, but her oral temperature observed during that treatment was not in the hypothermic range. This is an argument in favour of olanzapine as the primary cause of her hypothermia.

Since the introduction of the drug in 1996 for clinical use, the database of the Adverse Drug Reactions linked in 2006 hypothermia to olanzapine use. The underlying mechanisms are still unclear. In 2000 Oerther and Ahlenus made the suggestion that olanzapine-induced hypothermia may be explained by a direct inhibitory effect on the sympathetic outflow and brown adipose tissue thermogenesis [18].

Metabolism of olanzapine is via CYP 1A2 pathways, with no relevant genetic polymorphisms currently on record [7,8]. It is known that in normal humans there is a balance between the down-regulation of the body temperature by dopamine and the up-regulation of the body temperature by serotonin. Hypothermia induced by olanzapine could be mediated through antagonism of mostly D2 receptors but also due to antagonism of the 5-HT₂ receptors, for which we now know that olanzapine has a high affinity [9].

We suspect that hypotension and bradycardia in our patient were provoked by olanzapine use, namely by blockage of the α_2 -adrenergic receptors [15]. The latter might also increase the hypothermic effect by inhibiting peripheral responses to cooling of the body [9].

5. SUMMARY AND CONCLUSION

Medication-induced hypothermia can go unnoticed in patients, and in extreme cases can be life-threatening. The symptoms and signs are delirium, slurred speech, ataxia, shivering, subjective coldness, fatigue, incoordination and bradycardia. These can be mistaken for symptoms seen in an acute state of undernutrition in anorexic patients. Therefore, when antipsychotic drugs are prescribed or increased in dosage, clinicians should be aware of drug-induced hypothermia. In such a context, it is necessary to monitor body temperature very carefully, registering in detail the temperature and vital signs along with the correct dosage of the drug and the time interval of increase in dose.

REFERENCES

[1] Bymaster, F.P., Hemrick-Luecke, S.K., Perry, K.W. and

Fuller, R.W. (1996) Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α_1 -adrenergic and muscarinic, receptors *in vivo* in rats. *Psychopharmacology*, **124**, 87-94. [doi:10.1007/BF02245608](https://doi.org/10.1007/BF02245608)

- [2] Bymaster, F.P., Nelson, D.L., DeLapp, N.W., Falcone, J.F., Eckols, K., Truex, L.L., Foreman, M.M., Lucaites, V.L. and Calligaro, D.O. (1999) Antagonism by olanzapine of dopamine D1, serotonin₂, muscarinic, histamine H₁ and α_1 -adrenergic receptors *in vitro*. *Schizophrenia Research*, **37**, 107-122. [doi:10.1016/S0920-9964\(98\)00146-7](https://doi.org/10.1016/S0920-9964(98)00146-7)
- [3] Razaq, M. and Samma, M. (2004) A case of risperidone-induced hypothermia. *American Journal of Therapeutics*, **11**, 229-230. [doi:10.1097/00045391-200405000-00012](https://doi.org/10.1097/00045391-200405000-00012)
- [4] Danzl, D. (2002) Hypothermia. *Seminars in Respiratory and Critical Care Medicine*, **23**, 57-68. [doi:10.1055/s-2002-20589](https://doi.org/10.1055/s-2002-20589)
- [5] Blass, D.M. and Chuen, M. (2004) Olanzapine-associated hypothermia. *Psychosomatics*, **45**, 135-139. [doi:10.1176/appi.psy.45.2.135](https://doi.org/10.1176/appi.psy.45.2.135)
- [6] Hägg, S., Mjörndal, T. and Lindqvist, L. (2001) Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine. *Journal of Clinical Psychopharmacology*, **21**, 113-115. [doi:10.1097/00004714-200102000-00023](https://doi.org/10.1097/00004714-200102000-00023)
- [7] Kreuzer, P., Landgrebe, M., Hajak, G., Burger, S.J. and Langguth, B. (2011) A case of severe hypothermia following single-dose administration of olanzapine: A case report. *Journal of Clinical Psychopharmacology*, 22 February 2011.
- [8] Kreuzer, P., Landgrebe, M., Wittmann, M., Hajak, G., Schencklmann, M., Poepl, T.B. and Langguth, B. (2011) Hypothermia under olanzapine treatment: Clinical case series and review of current literature. *Der Nervenarzt*, **83**, 630-637. [doi:10.1007/s00115-011-3310-y](https://doi.org/10.1007/s00115-011-3310-y)
- [9] Rasnayake, L.R., Wimalaratne, H., Jayapala, R.K., Gamage, C.D., Dassanayake, D.L., Ratnayake, S.L., Colombage, A., Nandadeva, D. and Nelumdeniya, A.N. (2011) An usual case of hypothermia associated with therapeutic doses of olanzapine: A case report. *Journal of Medical Case Reports*, **18**, 189.
- [10] Norris, M.L., Spettigue, W., Buchhol, A., Henderson, K.A., Gomez, R., Maras, D., Gaboury, I. and Ni, A. (2011) Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa. *Journal of Child and Adolescent Psychopharmacology*, **21**, 213-220. [doi:10.1089/cap.2010.0131](https://doi.org/10.1089/cap.2010.0131)
- [11] Hein, I.M. and Huyser, C. (2010) Olanzapine in de behandeling van adolescenten met anorexia nervosa. *Tijdschrift voor Psychiatrie*, **52**, 417-421.
- [12] Phan, T.G., Yu, R.Y. and Hersch, M. (1998) Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome. *Medical Journal of Australia*, **169**, 230-231.
- [13] Parris, C., Mack, J.M., Cochiolo, J.A., Steinmann, A.F. and Tietjen, J. (2001) Hypothermia in 2 patients treated with atypical antipsychotic medication. *Journal of Clinical Psychopharmacology*, **62**, 61-63.

- [doi:10.4088/JCP.v62n0112g](https://doi.org/10.4088/JCP.v62n0112g)
- [14] Fukunishi, I., Sato, Y., Kino, K., Shirai, T. and Kitaoka, T. (2003) Hypothermia in a hemodialysis patient treated with olanzepine monotherapy. *Journal of Clinical Psychopharmacology*, **23**, 314.
[doi:10.1097/00004714-200306000-00013](https://doi.org/10.1097/00004714-200306000-00013)
- [15] Lee, T.W., Tsai, S.J. and Hwang, J.P. (2003) Severe cardiovascular side effects of olanzapine in an elderly patient: Case report. *The International Journal of Psychiatry in Medicine*, **33**, 399-401.
[doi:10.2190/U99G-XDML-0GRG-BYE0](https://doi.org/10.2190/U99G-XDML-0GRG-BYE0)
- [16] Hung, C.F., Huang, T.Y. and Lin, P.Y. (2009) Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder. *General Hospital Psychiatry*, **31**, 376-378.
[doi:10.1016/j.genhosppsych.2008.09.009](https://doi.org/10.1016/j.genhosppsych.2008.09.009)
- [17] Muñoz, M.T. and Argente, J. (2002) Anorexia nervosa in female adolescents: Endocrine and bone mineral density disturbances. *European Journal of Endocrinology*, **147**, 275-286. [doi:10.1530/eje.0.1470275](https://doi.org/10.1530/eje.0.1470275)
- [18] Oerther, S. and Ahlenius, S. (2000) Atypical antipsychotics and dopamine D(1) receptor agonism: An *in vivo* experimental study using core temperature measurements in the rat. *Journal of Pharmacology and Experimental Therapeutics*, **29**, 731-736.